Abiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate Cancer

This study is looking at how well two hormone-blocking treatments — abiraterone (with prednisone) and darolutamide — work in real-world patients with advanced prostate cancer, to better understand which patients benefit most from each drug. **You may be eligible if...** - You are 18 or older with a confirmed diagnosis of advanced prostate cancer - Your doctor has recommended starting abiraterone acetate plus prednisone or darolutamide - You are currently on or eligible for androgen deprivation therapy (ADT — hormone therapy to lower testosterone), or have had surgical castration - You have a reasonable performance status and expected life expectancy of at least 6 months **You may NOT be eligible if...** - You have already been on abiraterone or darolutamide for more than 28 days before enrolling - You have a medical condition that would prevent you from safely participating or giving informed consent Talk to your doctor to see if this trial is right for you.